ReviewPhotochemistry and photobiology2023
Photodynamic Therapy for Bladder Cancers, A Focused Review
Review in Photochemistry and photobiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 45 citations in OpenAlex.
- Impact of Photodynamic Diagnosis on Immune Cell Infiltration in BCG-treated Non-muscle-invasive Bladder Cancer.European urology open science · 2026Article
- Prognostic prediction of incidental prostate cancer in radical cystoprostatectomy for muscle-invasive bladder cancer.International urology and nephrology · 2026Article
- Knowledge mapping of photodynamic therapy in bladder cancer: a bibliometric analysis (2000-2025).Translational andrology and urology · 2026Article
- Combining 5-ALA-PDT with berbamine as an in vitro multimodal therapy approach against bladder cancer cells.Scientific reports · 2026Article
- Empowering photodynamic therapy with artificial intelligence: current trends and future directions.Frontiers in oncology · 2026Review
- Preclinical translational screening of palladium(II)-porphyrin photosensitizers across human and Oncopig bladder cancer cell lines.Frontiers in oncology · 2026Article
- Beyond light scattering: the effects of intralipid on benzoporphyrin derivative-sensitized photodynamic treatment in ovarian cancer cells.Journal of biomedical optics · 2025Article
- Emerging uses of 5-aminolevulinic-acid-induced protoporphyrin IX in medicine: a review of multifaceted, ubiquitous, molecular diagnostic, therapeutic, and theranostic opportunities.Journal of biomedical optics · 2025Review
- Nanomedicine Approaches for Autophagy Modulation in Cancer Therapy.Small science · 2025Article
- Article
- A Comprehensive Review of Current Approaches in Bladder Cancer Treatment.ACS pharmacology & translational science · 2025Review
- Prognostic value and molecular mechanism of photodynamic therapy and apoptosis related gene FGFR1 in bladder cancer.Frontiers in oncology · 2025Article
- Combined use of 5-ALA-induced protoporphyrin IX and chlorin e6 for fluorescence diagnostics and photodynamic therapy of skin tumors.Lasers in medical science · 2024Article
- Photodynamic Therapy: Past, Current, and Future.International journal of molecular sciences · 2024Review
- Full-course NIR-II imaging-navigated fractionated photodynamic therapy of bladder tumours with X-ray-activated nanotransducers.Nature communications · 2024Article
- NIR light-triggered photodynamic antibacterial nanofiber membrane based on polycaprolactone and phthalocyanine derivative for biomedical applications.RSC advances · 2024Article
- Photodynamic Therapy in the Treatment of Cancer-The Selection of Synthetic Photosensitizers.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Review
- Photodynamic Therapy: Current Trends and Potential Future Role in the Treatment of Bladder Cancer.International journal of molecular sciences · 2024Review
- Complexes of Ruthenium(II) as Promising Dual-Active Agents against Cancer and Viral Infections.Pharmaceuticals (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Bladder cancer is the first cancer for which PDT was clinically approved in 1993. Unfortunately, it was unsuccessful due to side effects like bladder contraction. Here, we summarized the recent progress of PDT for bladder cancers, focusing on photosensitizers and formulations. General strategies to minimize side effects are intravesical administration of photosensitizers, use of targeting strategies for photosensitizers and better control of light. Non-muscle invasive bladder cancers are more suitable for PDT than muscle invasive and metastatic bladder cancers. In 2010, the FDA approved blue light cystoscopy, using PpIX fluorescence, for photodynamic diagnosis of non-muscle invasive bladder cancer. PpIX produced from HAL was also used in PDT but was not successful due to low therapeutic efficacy. To enhance the efficacy of PpIX-PDT, we have been working on combining it with singlet oxygen-activatable prodrugs. The use of these prodrugs increases the therapeutic efficacy of the PpIX-PDT. It also improves tumor selectivity of the prodrugs due to the preferential formation of PpIX in cancer cells resulting in decreased off-target toxicity. Future challenges include improving prodrugs and light delivery across the bladder barrier to deeper tumor tissue and generating an effective therapeutic response in an In vivo setting without causing collateral damage to bladder function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.